Primmune Therapeutics logo

Primmune Therapeutics

Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.

Industries

Employees

1-10

Links


Org chart

Collapse

Board & advisors


Teams


Offices